Newsfeeds - Spark Newswire

4 minute read

COMPASS Pathways: New Data & Insight On Psilocybin Therapy For Treatment-Resistant Depression

March 14, 6:05 PM

COMPASS Pathways' (NASDAQ: CMPS) Phase 2b study of synthetic psilocybin COMP360 paired with psychological support for Treatment-Resistant Depression (TR

CMPS

1 minute read

HC Wainwright & Co. Reiterates Buy on Compass Pathways, Maintains $120 Price Target

By Benzinga Newsdesk

March 10, 7:20 AM

HC Wainwright & Co. analyst Patrick Trucchio reiterates Compass Pathways (NASDAQ:CMPS) with a Buy and maintains $120 price target.

CMPS

3 minute read

Legal
News

‘Oklahoma House Approves Psilocybin Bill Protecting Patients From Prosecution And Promoting Research’ – Marijuana Moment

By Happy Mohamed

March 9, 2:10 PM

https://www.marijuanamoment.net/oklahoma-house-approves-psilocybin-bill-protecting-patients-from-prosecution-and-promoting-research/ The Oklahoma House of Representatives has approved a bill to promote research into the

CMPS

4 minute read

Legal
News

‘Hawaii Senate Approves Marijuana Legalization And Psychedelic Research Bills’ – Marijuana Moment

By Happy Mohamed

March 7, 4:49 PM

https://www.marijuanamoment.net/hawaii-senate-approves-marijuana-legalization-and-psychedelic-research-bills/

ACB

6 minute read

Psyched: 9 US Reform Bills, Ayahuasca ‘A Release’ For Prince Harry, At-Home Therapy & More

By Lara Goldstein

March 7, 11:29 AM

Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been held and various measures have been considered around the legalization of psychedelics. Let’s go over the latest proposed regulations.

AGNPF

3 minute read

Here Are The Year’s Highest Priced Psychedelics Stocks In US Markets

By Lara Goldstein

March 6, 1:41 PM

After everything that's happened in the last several years, we believe it's safe to say that the psychedelic renaissance is a reality, one that Benzinga has consistently reported on.

ATAI

2 minute read

COMPASS Pathways Shares Q4 & Year-End 2022 Financials, Advances Phase 3 Psilocybin Trials

By Lara Goldstein

February 28, 3:55 PM

Mental healthcare biotech COMPASS Pathways (NASDAQ: CMPS) reported its financial results for the fourth quarter and year-end 2022 and provided an update on recent pipeline and business progress. Numbers show:

CMPS

2 minute read

John Oliver’s Take On Psychedelic Assisted Therapy: There’s Huge Potential If Done Responsibly

By Javier Hasse

February 20, 10:55 AM

John Oliver is back on "Last Week Tonight" and is once again taking a deep dive into a very intriguing topic: the potential benefits of psychedelic-assisted therapy. The show, which aired on Sunday, delves into the history of psychedelics and its potential benefits for mental health.

CMPS

3 minute read

‘Hawaii Senators Approve Bill To Promote Research Into Psilocybin And MDMA Therapy’ – Marijuana Moment

By Happy Mohamed

February 13, 12:49 PM

https://www.marijuanamoment.net/hawaii-senators-approve-bill-to-promote-research-into-psilocybin-and-mdma-therapy/ Hawaii senators have approved a bill in committee to promote research into the therapeutic potential of

CMPS

3 minute read

10 Short Squeeze Candidates To Watch This Week: Getty, Lannett, AirSculpt And More

By Chris Katje

February 13, 12:23 PM

Potential short squeeze plays gained steam in 2021 and continued through 2022, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits that could lead to a short squeeze.

AIRS